Literature DB >> 28005462

Recognition of c9orf72 Mutant RNA by Single-Stranded Silencing RNAs.

Jiaxin Hu1,2, Frank Rigo3, Thazha P Prakash3, David R Corey1,2.   

Abstract

Mutations within the chromosome 9 open reading frame 72 (c9orf72) gene are associated with both familial amyotrophic lateral sclerosis and frontotemporal dementia. The mutation leads to an expanded GGGGCC hexanucleotide repeat within the first intron of c9orf72 and an expanded CCCCGG repeat within a corresponding antisense transcript. Both the mutant intronic and antisense RNAs have been implicated in disease. We have previously reported that duplex RNAs complementary to the repeats can recognize disease-causing RNA and block detection of nuclear foci formed by the mutant transcripts. Here, we test the hypothesis that inhibition can also be achieved by single-stranded silencing RNAs (ss-siRNAs). ss-siRNAs are single-stranded antisense oligonucleotides (ASOs) that function through RNAi interference (RNAi) to silence gene expression. ss-siRNAs can block the expanded repeats within both intronic RNA and the antisense transcripts. Inhibition is more potent than by analogous duplex RNAs. Our data suggest that the potent effects on foci are caused by a combination of mechanisms including RNAi and direct binding of the ss-siRNA to the target transcripts. These findings reinforce the suggestion that ss-siRNAs combine the favorable properties of duplex RNA and single-stranded ASOs.

Entities:  

Keywords:  RNA interference; antisense oligonucleotide; c9orf72; single-strand silencing RNA

Mesh:

Substances:

Year:  2016        PMID: 28005462      PMCID: PMC5372765          DOI: 10.1089/nat.2016.0655

Source DB:  PubMed          Journal:  Nucleic Acid Ther        ISSN: 2159-3337            Impact factor:   5.486


  21 in total

1.  Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS.

Authors:  Mariely DeJesus-Hernandez; Ian R Mackenzie; Bradley F Boeve; Adam L Boxer; Matt Baker; Nicola J Rutherford; Alexandra M Nicholson; NiCole A Finch; Heather Flynn; Jennifer Adamson; Naomi Kouri; Aleksandra Wojtas; Pheth Sengdy; Ging-Yuek R Hsiung; Anna Karydas; William W Seeley; Keith A Josephs; Giovanni Coppola; Daniel H Geschwind; Zbigniew K Wszolek; Howard Feldman; David S Knopman; Ronald C Petersen; Bruce L Miller; Dennis W Dickson; Kevin B Boylan; Neill R Graff-Radford; Rosa Rademakers
Journal:  Neuron       Date:  2011-09-21       Impact factor: 17.173

Review 2.  Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides.

Authors:  Richard S Geary; Daniel Norris; Rosie Yu; C Frank Bennett
Journal:  Adv Drug Deliv Rev       Date:  2015-02-07       Impact factor: 15.470

3.  Single-stranded siRNAs activate RNAi in animals.

Authors:  Walt F Lima; Thazha P Prakash; Heather M Murray; Garth A Kinberger; Wenyu Li; Alfred E Chappell; Cheryl S Li; Susan F Murray; Hans Gaus; Punit P Seth; Eric E Swayze; Stanley T Crooke
Journal:  Cell       Date:  2012-08-31       Impact factor: 41.582

4.  Single-stranded microRNA mimics.

Authors:  Guillaume Chorn; Molly Klein-McDowell; Lihong Zhao; Matthew A Saunders; W Michael Flanagan; Aarron T Willingham; Lee P Lim
Journal:  RNA       Date:  2012-08-21       Impact factor: 4.942

5.  Systematic chemical modifications of single stranded siRNAs significantly improved CTNNB1 mRNA silencing.

Authors:  Wonsuk Chang; Yi Pei; Erin N Guidry; Daniel Zewge; Craig A Parish; Edward C Sherer; Jillian DiMuzio; Hangchun Zhang; Victoria J South; Walter R Strapps; Laura Sepp-Lorenzino; Steven L Colletti; Matthew G Stanton
Journal:  Bioorg Med Chem Lett       Date:  2016-07-28       Impact factor: 2.823

Review 6.  The delivery of therapeutic oligonucleotides.

Authors:  Rudolph L Juliano
Journal:  Nucleic Acids Res       Date:  2016-04-15       Impact factor: 16.971

7.  Transcriptional silencing by single-stranded RNAs targeting a noncoding RNA that overlaps a gene promoter.

Authors:  Masayuki Matsui; Thazha P Prakash; David R Corey
Journal:  ACS Chem Biol       Date:  2012-10-24       Impact factor: 5.100

8.  Engineering Duplex RNAs for Challenging Targets: Recognition of GGGGCC/CCCCGG Repeats at the ALS/FTD C9orf72 Locus.

Authors:  Jiaxin Hu; Jing Liu; Liande Li; Keith T Gagnon; David R Corey
Journal:  Chem Biol       Date:  2015-11-12

9.  Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD/ALS.

Authors:  Tania F Gendron; Kevin F Bieniek; Yong-Jie Zhang; Karen Jansen-West; Peter E A Ash; Thomas Caulfield; Lillian Daughrity; Judith H Dunmore; Monica Castanedes-Casey; Jeannie Chew; Danielle M Cosio; Marka van Blitterswijk; Wing C Lee; Rosa Rademakers; Kevin B Boylan; Dennis W Dickson; Leonard Petrucelli
Journal:  Acta Neuropathol       Date:  2013-10-16       Impact factor: 17.088

10.  Cellular localization of long non-coding RNAs affects silencing by RNAi more than by antisense oligonucleotides.

Authors:  Kim A Lennox; Mark A Behlke
Journal:  Nucleic Acids Res       Date:  2015-11-17       Impact factor: 16.971

View more
  12 in total

Review 1.  The polyG diseases: a new disease entity.

Authors:  Tongling Liufu; Yilei Zheng; Jiaxi Yu; Yun Yuan; Zhaoxia Wang; Jianwen Deng; Daojun Hong
Journal:  Acta Neuropathol Commun       Date:  2022-05-31       Impact factor: 7.578

2.  Activating frataxin expression by single-stranded siRNAs targeting the GAA repeat expansion.

Authors:  Xiulong Shen; Audrius Kilikevicius; Daniel O'Reilly; Thazha P Prakash; Masad J Damha; Frank Rigo; David R Corey
Journal:  Bioorg Med Chem Lett       Date:  2018-07-21       Impact factor: 2.823

Review 3.  C9orf72-mediated ALS and FTD: multiple pathways to disease.

Authors:  Rubika Balendra; Adrian M Isaacs
Journal:  Nat Rev Neurol       Date:  2018-09       Impact factor: 42.937

Review 4.  Gene therapy for ALS: A review.

Authors:  Defne A Amado; Beverly L Davidson
Journal:  Mol Ther       Date:  2021-04-09       Impact factor: 11.454

5.  Development of a sensitive trial-ready poly(GP) CSF biomarker assay for C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis.

Authors:  Katherine M Wilson; Eszter Katona; Idoia Glaria; Mireia Carcolé; Imogen J Swift; Aitana Sogorb-Esteve; Carolin Heller; Arabella Bouzigues; Amanda J Heslegrave; Ashvini Keshavan; Kathryn Knowles; Saurabh Patil; Susovan Mohapatra; Yuanjing Liu; Jaya Goyal; Raquel Sanchez-Valle; Robert Jr Laforce; Matthis Synofzik; James B Rowe; Elizabeth Finger; Rik Vandenberghe; Christopher R Butler; Alexander Gerhard; John C Van Swieten; Harro Seelaar; Barbara Borroni; Daniela Galimberti; Alexandre de Mendonça; Mario Masellis; M Carmela Tartaglia; Markus Otto; Caroline Graff; Simon Ducharme; Jonathan M Schott; Andrea Malaspina; Henrik Zetterberg; Ramakrishna Boyanapalli; Jonathan D Rohrer; Adrian M Isaacs
Journal:  J Neurol Neurosurg Psychiatry       Date:  2022-04-04       Impact factor: 13.654

6.  Targeting RNA-Mediated Toxicity in C9orf72 ALS and/or FTD by RNAi-Based Gene Therapy.

Authors:  Raygene Martier; Jolanda M Liefhebber; Ana García-Osta; Jana Miniarikova; Mar Cuadrado-Tejedor; Maria Espelosin; Susana Ursua; Harald Petry; Sander J van Deventer; Melvin M Evers; Pavlina Konstantinova
Journal:  Mol Ther Nucleic Acids       Date:  2019-02-11

7.  Inducible expression of human C9ORF72 36x G4C2 hexanucleotide repeats is sufficient to cause RAN translation and rapid muscular atrophy in mice.

Authors:  F W Riemslagh; E C van der Toorn; R F M Verhagen; A Maas; L W J Bosman; R K Hukema; R Willemsen
Journal:  Dis Model Mech       Date:  2021-01-11       Impact factor: 5.758

8.  Optimization in Chemical Modification of Single-Stranded siRNA Encapsulated by Neutral Cytidinyl/Cationic Lipids.

Authors:  Zheng Li; Xixian Wang; Xinyang Zhou; Jie Wang; Zhu Guan; Zhenjun Yang
Journal:  Front Chem       Date:  2022-03-07       Impact factor: 5.221

Review 9.  Disease Mechanisms and Therapeutic Approaches in C9orf72 ALS-FTD.

Authors:  Keith Mayl; Christopher E Shaw; Youn-Bok Lee
Journal:  Biomedicines       Date:  2021-05-25

10.  Therapeutic Development for CGG Repeat Expansion-Associated Neurodegeneration.

Authors:  Keqin Xu; Yujing Li; Emily G Allen; Peng Jin
Journal:  Front Cell Neurosci       Date:  2021-05-12       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.